Alpha Tau Medical Ltd. Announces Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at DDW 2026

Alpha Tau Medical Ltd. announced that an abstract detailing results from two clinical trials of its Alpha DaRT® therapy in pancreatic cancer patients has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026. This marks the first time clinical results for Alpha DaRT in pancreatic cancer will be presented at a major gastroenterology conference. The abstract, titled “Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,” will be presented on May 2, 2026. The presentation will be led by Dr. Harold Jacob, based on data from trials conducted at Hadassah Medical Center. CEO Uzi Sofer highlighted this as a milestone, emphasizing Alpha DaRT's potential for inoperable pancreatic cancer patients. Dr. Robert Den, Chief Medical Officer, noted the scientific rigor and clinical significance of the work, which informs the company's ongoing clinical development program. The filing also includes standard forward-looking statements and risk factors associated with the company's technology and operations.